20.500.12556/RUL-143240 Lipidation of NOD2 agonists with adamantane and stearoyl moieties differentially regulates their In vivo adjuvant activity NOD2 is an innate immune receptor that constitutes an important target for the development of small molecule immunopotentiators with great potential to be used as vaccine adjuvants. We report here the results of an in vivo study of the adjuvant properties of a desmuramylpeptide NOD2 agonist SG29 and its lipidated analogs featuring an adamantyl moiety or a stearoyl group. These compounds have been synthesized, incorporated into liposomes, and evaluated for their in vivo adjuvant activity. The characterization of liposome formulations of examined compounds revealed that their size increased in comparison to that of empty liposomes. The introduction of a stearoyl or an adamantane lipophilic anchor into the structure of SG29, to produce SG115 and ZSB63, respectively, substantially improved the in vivo adjuvant activity. Of note, the attachment of the stearoyl moiety produced a Th2-biased immune response, while the incorporation of the adamantyl moiety greatly enhanced the production of total IgG but mostly augmented the production of IgG2a antibodies, which indicated a shift toward a Th1 immune response. The identified bona fide capacity of ZSB63 to initiate a cellular immune response thus highlights its untapped potential as an alternative vaccine adjuvant. NOD2 agonist vaccine adjuvant adamantane immunopotentiators desmuramylpeptides agonisti NOD2 adjuvans za cepivo adamantan imunopotenciatorji desmuramilpeptidi true false true Angleški jezik Slovenski jezik Članek v reviji 2022-12-09 08:15:32 2022-12-09 08:15:34 2022-12-10 03:51:17 0000-00-00 00:00:00 2022 0 0 9 str. iss. 12, art. 2755 Vol. 14 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 615.4:54:616-097 1999-4923 10.3390/pharmaceutics14122755 133033219 pharmaceutics-14-02755.pdf pharmaceutics-14-02755.pdf 1 CAA8038FCF6A548E07255B70BFDF4D36 320764ded8c570e1f15f7a308ac81f83089d4b58c929b1005dbadbea73eb72df 7d7e9419-7791-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=164862 https://www.mdpi.com/1999-4923/14/12/2755 1 1dc31b4a-7791-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=164861 Fakulteta za farmacijo 0 0 0